NDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
hormone, somatostatin. It is an even more potent inhibitor of GH, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses luteinizing hormone (LH) response to gonadotropin releasing hormone (GnRH), decreases splanchnic blood flow, and inhibits release of serotonin, gastrin,…
Clinical Trials (5)
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Started Nov 2011
255 enrolled
Neuroendocrine TumorsAdvanced Cancer
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
Started May 2010
43 enrolled
Neuroendocrine Carcinoma
Sandostatine® LP and Hyperinsulinism
Started May 2009
10 enrolled
Congenital Hyperinsulinism
Sandostatin for Patients With Androgen Independent Prostate Cancer
Started Jul 2007
13 enrolled
Prostate Cancer
Effects of Sandostatin LAR® in Acromegaly
Started Oct 2006
21 enrolled
Acromegaly